News

Enrollment is now complete in the LIFT-AD clinical trial evaluating Athira Pharma‘s fosgonimeton, an experimental treatment for mild-to-moderate Alzheimer’s disease. The Phase 2/3 study (NCT04488419) enrolled about 315 participants, who received either 40 mg fosgonimeton or a placebo for 26 weeks (about six months). Top-line data is expected in…

A tool called focused ultrasound, or FUS, may be a safe and promising way to help antibody-based treatments better reach the brain, and clear away toxic amyloid-beta protein clumps (aggregates), in people with Alzheimer’s disease. The approach involves using targeted sound waves to temporarily open up the selective blood-brain…

The cell therapy candidate Lomecel-B significantly improved cognitive function and reduced brain volume loss relative to a placebo in a Phase 2a clinical trial of people with mild Alzheimer’s disease, according to new data announced by the treatment’s developer Longeveron. “We believe these new data may provide evidence…

A rare variant in the APOE gene, known as the Christchurch mutation or APOE3ch, can protect against the development of Alzheimer’s disease by stopping the spread of toxic clumps of the tau protein in the brain, a new study suggests. The findings may have implications for better understanding Alzheimer’s underlying…

A proof-of-concept Phase 2b clinical trial evaluating the safety and efficacy of Advantage Therapeutics’ investigational immunotherapy AD04 in people with mild Alzheimer’s disease has enrolled its first patient. The placebo-controlled study is being conducted in Austria, France, Poland, Bulgaria, and Slovakia, and is expected to open clinical sites in Germany and…

NE3107, BioVie Pharma’s experimental oral therapy, was superior to a placebo at improving performance of adults with mild-to-moderate Alzheimer’s disease on all cognitive and functional assessments of a Phase 3 clinical trial, top-line efficacy data shows. However, these differences failed to reach statistical significance due to a loss…

A novel technique that detects DNA from dead nerve cells in the blood may help diagnose Alzheimer’s disease and predict its development with a five-year window among people with mild cognitive impairment, a new study showed. The work was led by scientists at Resonant, a subsidiary of…

T3D-959, an oral medication in the pipeline of T3D Therapeutics, outperformed a placebo at improving cognitive function in people with mild to moderate Alzheimer’s disease who have a high pTau-217/Non-pTau-217 ratio, a new marker of the disease. That’s according to top-line results from the Phase 2…

With November comes National Alzheimer’s Awareness Month, an annual effort to recognize the impact of the neurodegenerative disease in the U.S., where about 6.2 million people are affected by it. Each November, the Alzheimer’s Foundation of America (AFA) offers supporters a range of different ways to raise awareness…

Weekly injections of an investigational formulation of the Alzheimer’s disease therapy Leqembi (lecanemab) worked better than the approved treatment in removing harmful amyloid beta plaques from patients’ brains over six months in a Phase 3 trial. In fact, the subcutaneous or under-the-skin formulation cleared 14% more plaques in…